Source - RNS
RNS Number : 2626W
Tiziana Life Sciences PLC
15 April 2019
 

Tiziana Life Sciences plc
("Tiziana" or the "Company")

 

TR-1 - Notification of Major Holdings

 

New York/London, 15 April 2019 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and development of innovative therapeutics for inflammation and oncology indications, today releases the TR-1 forms appended to this announcement.

 

The Company understands that the resultant stake in its share capital held by Quilter plc, as nominee for certain underlying shareholders, is due to the transfer of existing shareholdings from Beaufort Securities Limited (in administration), and not due to any recent on-market purchases.

 

About Tiziana Life Sciences

Tiziana is a UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology. In addition to milciclib, the Company is also developing Foralumab for liver diseases. Foralumab is the only fully human anti-CD3 mAbs in clinical development in the world. This compound has potential application in a wide range of autoimmune and inflammatory diseases, such as nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBS), ulcerative colitis, multiple sclerosis, type-1 diabetes (T1D), inflammatory bowel disease (IBD), psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable.

 

For more information go to http://www.tizianalifesciences.com

Contacts:

Tiziana Life Sciences plc

Gabriele Cerrone, Chairman and founder

 

+44 (0)20 7493 2853

Cairn Financial Advisers LLP (Nominated adviser)

Liam Murray / Jo Turner

 

+44 (0)20 7213 0883

Stockdale Securities (Nominated brokers)

Antonio Bossi / Andy Crossley

 

+44 (0)20 7601 6125

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
HOLUVONRKKASAAR